Develops genetic medicine candidates, led by gene therapies for inherited heart diseases, for people with cardiovascular and genetic diseases.
10-K for FY2025, filed Mar 30, 2026We are a clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change…View ↗
Utilizing a stepwise, capital-efficient development approach, we are leveraging early proof-of-concept functional and biomarker data to…View ↗
LX2006 is an AAVrh10-based gene therapy candidate designed to intravenously deliver a functional frataxin, or FXN, gene for the treatment…View ↗
LX2020 is an AAVrh10-based gene therapy candidate designed to intravenously deliver a functional PKP2 gene to cardiac muscle for the…View ↗
LX2021 is a gene therapy candidate we are developing to intravenously deliver the coding sequence for the functional connexin 43, or Cx43…View ↗
LX2022 is a gene therapy candidate we are developing to intravenously deliver a functional TNNI3 gene to myocardial cells to treat a…View ↗
10-Q for Q3 FY2026, filed Nov 16, 2026
−$38.3MView ↗
8-K, filed Sep 29, 2026
Item 2.01 Completion of Acquisition or Disposal of Assets.View ↗
Competes with Solid Biosciences, Voyager Therapeutics, Neurocrine Biosciences, Larimar Therapeutics, PTC Therapeutics, Reata Pharmaceuticals, Biogen, Rocket Pharmaceuticals, and Tenaya Therapeutics
10-K for FY2025, filed Mar 30, 2026We are aware that our competitors are developing product candidates for the treatment of diseases that our product candidates will target.…View ↗
Loading...